Vanda Pharmaceuticals’ (VNDA) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a research report sent to investors on Wednesday,Benzinga reports. They currently have a $20.00 price objective on the biopharmaceutical company’s stock.

A number of other equities analysts have also commented on VNDA. B. Riley assumed coverage on shares of Vanda Pharmaceuticals in a report on Wednesday, November 5th. They issued a “buy” rating and a $11.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research note on Wednesday, October 8th. Cantor Fitzgerald lowered their price target on Vanda Pharmaceuticals from $13.00 to $11.00 and set an “overweight” rating on the stock in a research report on Thursday, October 30th. Finally, Wall Street Zen upgraded Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 1st. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $14.00.

Vanda Pharmaceuticals Stock Down 0.8%

NASDAQ:VNDA opened at $4.80 on Wednesday. The stock has a market cap of $283.67 million, a P/E ratio of -3.38 and a beta of 0.78. The business’s 50-day moving average price is $4.92 and its two-hundred day moving average price is $4.66. Vanda Pharmaceuticals has a twelve month low of $3.81 and a twelve month high of $5.70.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings data on Wednesday, October 29th. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.07). The company had revenue of $56.26 million during the quarter, compared to the consensus estimate of $58.73 million. Vanda Pharmaceuticals had a negative return on equity of 16.44% and a negative net margin of 39.70%. Vanda Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities research analysts expect that Vanda Pharmaceuticals will post -1.12 EPS for the current fiscal year.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Krensavage Asset Management LLC raised its stake in shares of Vanda Pharmaceuticals by 15.2% during the third quarter. Krensavage Asset Management LLC now owns 1,180,388 shares of the biopharmaceutical company’s stock valued at $5,890,000 after acquiring an additional 155,505 shares during the last quarter. PharVision Advisers LLC purchased a new position in Vanda Pharmaceuticals during the 3rd quarter valued at about $285,000. Quarry LP bought a new position in Vanda Pharmaceuticals during the 3rd quarter valued at approximately $53,000. Qube Research & Technologies Ltd bought a new position in Vanda Pharmaceuticals during the 3rd quarter valued at approximately $894,000. Finally, Mercer Global Advisors Inc. ADV purchased a new stake in Vanda Pharmaceuticals in the 3rd quarter worth approximately $145,000. Hedge funds and other institutional investors own 88.14% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.